8月21日 - ** Werewolf Therapeutics（HOWL.O）股价在盘前交易中上涨141%，至1.04美元
** Werewolf将通过全股票交易与私营公司Ambros Therapeutics合并
** 两家公司已获得1.5亿美元新融资，预计将支持运营及临床试验直至2029年初
** 合并后的公司将专注于开发一种名为neridronate的药物，用于治疗CRPS-1——这是一种剧痛性疾病，目前尚无获FDA批准的治疗方法
** 该药物目前处于后期临床试验阶段，关键结果预计将于2028年公布
** 合并预计于2027年第一季度完成，合并后公司将以Ambros Therapeutics的名义运营，并在纳斯达克交易所上市，股票代码为“AMBX”
** 美国食品药品监督管理局（FDA）已授予neridronate“突破性疗法”、“快速通道”及“孤儿药”资格
** 截至上一交易日收盘，HOWL今年以来累计下跌约32%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.